Related Experiment Video
Updated: Jul 17, 2026
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges
Qing You1, Xiao-Bing Lan1, Ning Liu2
1Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China.
Insights
This review explores neuroprotective agents for neonatal hypoxic-ischemic brain damage (HIBD). It analyzes molecular pathways of drugs in animal models to aid clinical translation for HIBD treatment.
Area of Science:
- Neuroscience
- Neonatal Medicine
- Pharmacology
Background:
- Neonatal hypoxic-ischemic brain damage (HIBD) causes significant mortality and long-term disability in newborns.
- Understanding HIBD mechanisms is crucial for effective pharmaceutical interventions.
- Current treatment options are limited due to the complexity of HIBD pathogenesis.
Purpose of the Study:
- To review neuroprotective agents targeting key pathogenic factors in neonatal HIBD.
- To analyze molecular pathways of these agents in animal models of HIBD.
- To provide a foundation for clinical translation of HIBD therapies.
Main Methods:
- Literature review of studies on neuroprotective agents for neonatal HIBD.
- Analysis of molecular mechanisms underlying drug efficacy in animal models.
- Focus on factors including oxidative stress, calcium overload, and apoptosis.
Main Results:
- Several classes of neuroprotective agents show promise in preclinical HIBD models.
- Specific drugs target pathways like oxidative stress, inflammation, and apoptosis.
- Detailed molecular mechanisms of action are elucidated for various agents.
Conclusions:
- Neuroprotective agents targeting multiple pathogenic pathways offer therapeutic potential for neonatal HIBD.
- Further research in animal models is essential to refine drug selection and dosing.
- Successful clinical translation requires a robust understanding of molecular targets and efficacy.
Abstract:
Neonatal hypoxic-ischemic brain damage (HIBD) is a prominent contributor to both immediate mortality and long-term impairment in newborns. The elusive nature of the underlying mechanisms responsible for neonatal HIBD presents a significant obstacle in the effective clinical application of numerous pharmaceutical interventions. This comprehensive review aims to concentrate on the potential neuroprotective agents that have demonstrated efficacy in addressing various pathogenic factors associated with neonatal HIBD, encompassing oxidative stress, calcium overload, mitochondrial dysfunction, endoplasmic reticulum stress, inflammatory response, and apoptosis. In this review, we conducted an analysis of the precise molecular pathways by which these drugs elicit neuroprotective effects in animal models of neonatal hypoxic-ischemic brain injury (HIBD). Our objective was to provide a comprehensive overview of potential neuroprotective agents for the treatment of neonatal HIBD in animal experiments, with the ultimate goal of enhancing the feasibility of clinical translation and establishing a solid theoretical foundation for the clinical management of neonatal HIBD.
